The hard-fought spirit of community mobilisation which informed a successful global fight against the HIV pandemic has been vastly undone by the twisted COVID response engineered by developed nations and Big Pharma
India's rare disease policy sets a Rs. 50 lakh ceiling. Roche's Risdiplam costs Rs. 72 lakhs a year. A generic alternative exists at a fraction of the price, but is tied up in patent litigation. Amidst this, rare disease patients are left to fight their own battles.
